Last checked at 28 Apr 2022 07:00
Tissue Regenix Group plc
("Tissue Regenix" or "the Group")
OrthoPure®XT clinical results presentation
Clinical results presented for OrthoPure®XT at 20th ESSKA Congress in Paris, France
Tissue Regenix Group (AIM:TRX), the regenerative medical devices company, announces that a podium presentation on the clinical experience with the Company's OrthoPure®XT, a novel xenograft biologic scaffold for certain anterior cruciate ligament (ACL) reconstruction procedures, will be presented at the 20th ESSKA (European Society for Sports Traumatology, Knee Surgery and Arthroscopy) Congress in Paris, France. At the conference, clinician Mr. Neil Hunt, the principal investigator for the study, will be presenting clinical results on the device's clinical safety and performance from a recently completed long-term prospective study.
OrthoPure®XT was awarded a CE Mark in June 2020 for revision of ACL reconstruction procedures and reconstruction of other knee ligaments, including multiligament and primary procedures when the autograft is unacceptable.
Mr. Neil Hunt is a consultant knee surgeon at York Teaching Hospitals NHS Foundation Trust, specialising in all aspects of knee surgery. He will be presenting data on Tissue Regenix's OrthoPure®XT ligament reconstruction implant which conclude that patients undergoing primary ACL reconstruction with this implant showed appropriate clinical safety and clinical performance at 48 months following treatment. These outcomes are in line with clinical expectations following primary ACL reconstruction and they indicate that OrthoPure®XT might provide an alternative graft choice for ACL reconstruction and other ligament reconstructions. Further studies are planned to evaluate this.
Further information on the abstract can be found here:
Title: | First In Human Clinical Data From A Novel Xenograft Biologic Scaffold Used To Treat Primary ACL Reconstruction. 24 & 48 Month Follow-Up |
The ESSKA Congress brings together industry experts in sports traumatology, knee surgery, and arthroscopy of ankle, knee, hip, shoulder, elbow and wrist and provides varied and innovative session formats covering all the latest updates, trends and techniques in these areas. More information on the conference can be found here.
Mr. Hunt, Consultant Knee Surgeon at York Teaching Hospitals NHS Foundation Trust, commented: "I am encouraged by the results of the 4-year clinical study with the OrthoPure®XT and look forward to additional clinical experience with this device. The OrthoPure®XT can be a biologic alternative which avoids the need to source a graft from the patient for knee ligament surgeries."
For more information:
Tissue Regenix Group plc David Cocke, Chief Financial Officer | www.tissueregenix.com Via Walbrook PR |
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Ben Maddison / Nick Harland | Tel: +44(0)20 7710 7600 |
Walbrook PR Ltd Alice Woodings / Lianne Applegarth | Tel: +44 (0)20 7933 8780 TissueRegenix@walbrookpr.com |
|
|
About Tissue Regenix (www.tissuergenix.com)
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or damaged body structures. Current applications address many critical clinical needs such as in sports medicine, foot and ankle, and wound care.
In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, dental, and ophthalmological surgical procedures.